Cases

Platforms like Meta and X (Twitter) use opaque algorithms to target and amplify political advertisements, often without disclosing why specific users see certain messages. In the EU, the Digital Services Act now requires ad libraries and targeting criteria disclosure, but the U.S. lacks equivalent rules. During the 2024 elections, microtargeted ads based on psychographic profiling have been used to suppress turnout or spread disinformation among vulnerable demographics. Advocates for transparency argue that voters cannot give informed consent if they don't understand how or why they're being targeted. Platforms counter that full transparency could expose proprietary systems and enable adversarial manipulation. This trial examines whether democratic accountability should override corporate secrecy in digital campaigning.

The 2024 global election supercycle—spanning over 50 countries including the U.S., India, and the EU—has seen an unprecedented rise in AI-generated audio and video deepfakes used in political messaging. In February 2024, a fake audio clip of President Biden discouraging voting in New Hampshire went viral, prompting emergency alerts from election officials. While some jurisdictions like the EU have enacted rules under the Digital Services Act requiring disclosure of synthetic media, the U.S. lacks federal regulation. This raises urgent questions about free speech, electoral integrity, and the state's role in moderating digital political discourse. Failure to act could erode trust in democratic processes; overregulation risks chilling legitimate satire and political commentary.

In 2026, the EU's Digital Product Passport (DPP) initiative will require detailed material disclosure for textiles, including fiber blends, dyes, and chemical treatments, accessible via QR codes. Proponents argue this enables recycling, informs consumers with allergies, and combats greenwashing. However, brands worry about revealing proprietary formulations and the cost of implementation. Pilot programs by H&M and Patagonia show mixed consumer engagement. This trial addresses whether mandatory QR-based transparency—beyond current labeling laws—should become a global standard for material honesty in fashion.

'Clean beauty'—a term implying non-toxic, safe ingredients—remains unregulated in the U.S. and most global markets. Brands use it liberally, yet formulations may still contain allergens, endocrine disruptors, or untested compounds. In early 2026, the FDA proposed a voluntary certification framework, while NGOs like EWG advocate for mandatory third-party audits. Meanwhile, dermatologists report rising contact dermatitis cases linked to 'clean' products containing natural but sensitizing botanicals. This trial questions whether the industry should adopt enforceable standards for 'clean' claims to protect consumer health and prevent misleading marketing.

The rise of 'bio-based' textiles—derived from plants, algae, or mycelium—has been touted as a sustainable alternative to petroleum-based synthetics. However, many such materials are not actually biodegradable under real-world conditions, and some require industrial composting facilities that are rarely available. In early 2026, the European Commission proposed stricter labeling rules for bio-based products, while the FTC in the U.S. is investigating greenwashing claims in apparel marketing. Brands like Stella McCartney and Pangaia promote bio-based innovations, yet independent lifecycle assessments often reveal limited end-of-life benefits. This raises a critical dilemma: should regulatory frameworks mandate proof of actual biodegradability before allowing 'bio-based' claims? The stakes involve consumer trust, environmental impact, and the integrity of circular economy initiatives.

Beauty brands like L'Oréal and Estée Lauder are increasingly using AI-generated 'virtual models' to showcase products, citing inclusivity, cost efficiency, and creative control. These digital avatars can represent diverse skin tones, ages, and features without the limitations of physical casting. However, dermatologists and consumer advocates warn that AI models often present unrealistic skin perfection, potentially exacerbating body image issues and undermining transparency about product efficacy. In 2026, the UK's Advertising Standards Authority began reviewing guidelines on digitally altered imagery, while the American Academy of Dermatology called for disclosure when AI models are used. This trial examines whether the benefits of AI models outweigh their psychological and ethical risks in beauty marketing.

Cities worldwide are rethinking public art after controversies over monuments and culturally insensitive installations. In 2025, municipalities like Minneapolis and Barcelona adopted policies requiring artists to engage local residents in the design process for publicly funded works. Proponents argue co-creation fosters ownership, reflects authentic community narratives, and prevents alienating or appropriative art. Critics—including many established artists—warn that committee-driven art dilutes vision, stifles challenging work, and conflates popularity with artistic merit. The tension lies between art as democratic expression versus art as individual genius. With public funding increasingly tied to equity goals, this question challenges foundational notions of authorship, aesthetic autonomy, and civic responsibility in the arts.

The NFT art market continues to evolve amid growing use of generative AI in creation processes. While some artists transparently integrate AI as a collaborative tool, others mint works without disclosing AI's role—raising authenticity and value concerns. In early 2025, major platforms like Foundation and Zora began debating mandatory disclosure policies after collectors discovered AI-generated elements in works marketed as 'hand-crafted.' The issue intersects with intellectual property, artistic labor, and collector trust. Traditional digital artists argue that undisclosed AI use constitutes deception, especially when pricing reflects human effort. AI artists counter that all tools evolve, and demanding disclosure stigmatizes innovation. With the NFT market seeking legitimacy post-hype, transparency may be key to sustainable growth—but at what cost to creative freedom?

Museums worldwide face increasing pressure to maintain both physical collections and digital archives. With climate change, aging infrastructure, and evolving audience expectations, institutions must allocate limited resources wisely. Recently, the Baltimore Museum of Art and others have explored deaccessioning works—selling pieces from their permanent collections—to fund operational needs, including digitization and digital conservation. The Association of Art Museum Directors (AAMD) historically restricted deaccessioning proceeds to acquiring new art, but temporarily relaxed these rules during the pandemic. Now, as digital access becomes central to public engagement and scholarship, some argue that using deaccession funds for digital preservation is a responsible adaptation. Opponents warn this sets a dangerous precedent, commodifying cultural heritage and risking the loss of public trust. This dilemma forces a reckoning: is digitizing art a form of preservation equal to conserving physical objects, and does it justify selling originals?

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have revolutionized weight management, originally developed for type 2 diabetes. While FDA-approved for obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27), growing off-label use among individuals with normal BMI (18.5–24.9) seeking body composition changes or metabolic 'optimization' raises ethical and safety concerns. Clinicians report increasing patient demand for these drugs despite limited long-term safety data in non-obese populations. Potential risks include muscle loss, gastrointestinal side effects, and unknown impacts on lean mass metabolism. Proponents argue for personal autonomy and potential cardiometabolic benefits even at lower BMIs, while critics warn of medicalizing normal body diversity and exacerbating body image disorders. This trial examines whether the benefits justify off-label use in non-obese individuals seeking weight loss or 'biohacking' advantages.